Insider Marcus Jewell to sell Cellebrite (CLBT) shares under Rule 144

Rhea-AI Filing Summary

Marcus Jewell filed a Rule 144 notice to sell 13,276 ordinary shares of Cellebrite DI Ltd., with an aggregate market value of $194,360.64, on or about February 17, 2026 through Morgan Stanley Smith Barney LLC on Nasdaq.

The filing notes 249,074,485 ordinary shares outstanding. Jewell acquired 31,728 ordinary shares on February 15, 2026 via vested restricted share units under an issuer S‑8 registered employee compensation plan. Over the prior three months, he sold 12,543, 9,592 and 1,779 shares, for gross proceeds of $230,372.06, $174,286.64 and $24,201.55.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary shares, par value NIS 0.00001	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 38th Floor New York NY 10004	13276	194360.64	249074485	02/17/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary shares, par value NIS 0.00001	02/15/2026	Restricted Share Units Vested Under an Issuer S-8 Registered Plan	Cellebrite DI Ltd.			31728	02/15/2026	Employee compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Marcus Jewell 94 Shlomo Shmelzer Road Petah Tikva L3 4970602	Ordinary shares, par value NIS 0.00001	11/17/2025	12543	230372.06
Marcus Jewell 94 Shlomo Shmelzer Road Petah Tikva L3 4970602	Ordinary shares, par value NIS 0.00001	11/18/2025	9592	174286.64
Marcus Jewell 94 Shlomo Shmelzer Road Petah Tikva L3 4970602	Ordinary shares, par value NIS 0.00001	02/12/2026	1779	24201.55

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filing for Cellebrite (CLBT) disclose?

The Form 144 discloses that insider Marcus Jewell plans to sell 13,276 Cellebrite ordinary shares under Rule 144. The shares have an aggregate market value of $194,360.64 and are expected to be sold on or about February 17, 2026 through Morgan Stanley Smith Barney LLC on Nasdaq.

How many Cellebrite (CLBT) shares is Marcus Jewell planning to sell?

Marcus Jewell plans to sell 13,276 Cellebrite ordinary shares according to the Form 144. The planned sale has an aggregate market value of $194,360.64, based on the figures reported, and will be executed through Morgan Stanley Smith Barney LLC on the Nasdaq market.

How did Marcus Jewell acquire the Cellebrite (CLBT) shares in this Form 144?

The filing shows Jewell acquired 31,728 ordinary shares on February 15, 2026 through vested restricted share units. These units vested under an issuer S‑8 registered employee compensation plan, with the consideration described as employee compensation rather than a cash purchase at the time of acquisition.

What recent Cellebrite (CLBT) share sales has Marcus Jewell reported?

Over the past three months, Jewell sold 12,543, 9,592 and 1,779 Cellebrite ordinary shares on November 17, 2025, November 18, 2025 and February 12, 2026. The gross proceeds from these sales were $230,372.06, $174,286.64 and $24,201.55, respectively, according to the disclosure.

How many Cellebrite (CLBT) shares are outstanding in this Form 144?

The Form 144 states that 249,074,485 ordinary shares of Cellebrite are outstanding. This number provides context for the scale of Jewell’s planned sale of 13,276 shares, showing it represents a very small portion of the total shares currently outstanding.

Which broker will handle the Cellebrite (CLBT) Rule 144 sale for Marcus Jewell?

The planned Rule 144 sale will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services. The broker’s listed address is 1 New York Plaza, 38th Floor, New York, NY 10004, and the shares are expected to be sold on the Nasdaq exchange.